Get started

Financials · RNXT

RenovoRx Inc. (RNXT) financials

For the twelve months ended Sep 30, 2026, RenovoRx Inc. reported $2.78M of revenue and -$13.02M of net income.

Revenue, TTM
$2.78M
Net income, TTM
-$13.02M
Net margin
-469.0%
Free cash flow, TTM
-$12.22M
EPS, diluted, TTM
-$0.31
Cash
$10.40M
P/S
20.51
Market cap
$56.9M
Annual revenue$1.12M
FY2024FY2025
Annual net income-$11.17M
FY2020FY2025
Annual free cash flow-$10.97M
FY2024FY2025

RNXT revenue and earnings growth

RNXT revenueQ3 2026$1.07M

Quarter YoY
+300.8%
QoQ
+17.3%
FY YoY
26x

RNXT revenue was $1.07M in fiscal Q3 2026 (ended Sep 30, 2026), up 300.8% from a year earlier and up 17.3% from the prior quarter. For the full fiscal 2025 it was $1.12M, up about 26-fold from fiscal 2024.

RNXT net incomeQ3 2026-$3.65M

RNXT net income was -$3.65M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$2.91M a year earlier. For the full fiscal 2025 it was -$11.17M, compared with -$8.81M in fiscal 2024.

RNXT EPSQ3 2026-$0.08

RNXT diluted EPS was -$0.08 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.08 a year earlier. For the full fiscal 2025 it was -$0.32.

RNXT free cash flowQ3 2026-$2.56M

RNXT free cash flow was -$2.56M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$2.27M a year earlier. For the full fiscal 2025 it was -$10.97M, compared with -$9.14M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Revenue$1.12M$43.0K----
Cost of revenue$327.0K$0----
Gross profit$796.0K$43.0K----
Research and development$6.27M$6.03M$5.67M$4.30M$3.04M$2.39M
Selling, general and admin$7.04M$4.99M$5.73M$5.65M$2.63M$818.0K
Operating income-$12.51M-$10.97M-$11.40M-$9.95M-$5.67M-$3.20M
Pre-tax income-$11.17M-$8.75M----
Income tax$2.0K-----
Net income-$11.17M-$8.81M-$10.23M-$9.89M-$6.32M-$3.80M
EPS, basic-$0.32-$0.40-$0.99-$1.09-$1.21-$1.72
EPS, diluted-$0.32-$0.40-$0.99-$1.09-$1.21-$1.72
Diluted shares35.3M22.3M10.3M9.1M5.2M2.2M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Cash and equivalents$7.02M$7.15M$1.17M$4.39M$15.19M$1.79M
Short-term investments---$2.05M--
Receivables$139.0K$43.0K----
Inventory$189.0K$0----
Current assets$7.89M$7.83M$1.47M$7.26M$16.28M$1.91M
Total assets$8.10M$8.12M$1.47M$7.26M$16.29M$1.91M
Current liabilities$1.96M$1.91M$1.18M$1.10M$938.0K$4.10M
Total liabilities$2.67M$3.64M$4.47M$1.10M$938.0K$4.12M
Shareholders' equity$5.42M$4.48M$3.00M$6.16M$15.35M-$14.66M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Operating cash flow-$10.97M-$9.13M-$10.26M-$8.81M-$5.92M-$3.53M
Capital expenditures$2.0K$12.0K----
Free cash flow-$10.97M-$9.14M----
Investing cash flow-$2.0K-$12.0K$2.03M-$2.03M-$15.0K-
Financing cash flow$10.85M$15.12M$5.01M$42.0K$19.33M$3.20M
Stock-based compensation$1.27M$1.17M$1.08M$644.0K$147.0K$33.0K
Depreciation and amortization$2.00M$0----

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Revenue growth, YoY2511.6%-----
Gross margin70.9%100.0%----
Operating margin-1114.0%-25511.6%----
Net margin-994.5%-20497.7%----
Free cash flow margin-977.3%-21248.8%----
Return on equity-206.0%-196.8%-341.1%-160.5%-41.2%-
Return on assets-138.0%-108.6%-698.0%-136.1%-38.8%-198.4%
Current ratio4.024.101.256.5917.360.47

Source: XBRL data RenovoRx Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

RNXT peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
RNXT$2.78M--$13.02M-469.0%$56.9M
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

RNXT FAQ

9 questions
  • What is RNXT revenue?
    RenovoRx Inc. (RNXT) reported $2.78M of revenue for the twelve months ended Sep 30, 2026. Revenue for fiscal 2025 was $1.12M.
  • Is RNXT profitable?
    No. RenovoRx Inc. reported a net loss of $13.02M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does RNXT have?
    RenovoRx Inc. reported $10.40M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is RNXT revenue growing?
    RenovoRx Inc.'s revenue changed 26x in fiscal 2025, to $1.12M.
  • What is RNXT gross margin?
    RenovoRx Inc.'s gross profit was $2.33M on $2.78M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 84.0%.
  • What is RNXT free cash flow?
    RenovoRx Inc. generated -$12.22M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$12.13M less capital expenditures.
  • What is RNXT earnings per share?
    Diluted earnings per share were -$0.31 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did RNXT last report financial results?
    The latest statements here come from RenovoRx Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this RNXT financial data come from?
    Quantisnow builds these statements from the structured XBRL data RenovoRx Inc. files with the SEC. It is provided for information only and is not investment advice.